Multiple sclerosis (MS) is a chronic neurodegenerative disease in which demyelination occurs. Demyelination is where the myelin or fatty lining of a neuron erodes, leading to damage in the central nervous system.

Over 90,000Canadians are affected by MS. It can cause bodily impairment ranging from blurred vision, to complete lack of muscle coordination and paralysis. Anastassia Voronova, an assistant professor at the University of Alberta and Canada research chair in Neural Stem Cell Biology, has done research on how to reverse demyelination.

In her research, published in Stem Cell, Voronova has discovered a way to target remyelination. This involves direct infusion of the brain molecule, fractalkine, which triggers the production of myelin.

She dietarily induced demyelination in the brains of mice to mimic the brain damage apparent in MS patients. She then injected fractalkine directly into their brains. The molecule consequently enhanced remyelination in the white and gray matter areas of the brain, despite experiencing damage from MS.

Fractalkine triggers progenitor cells descendants of stem cells which can create specialized cell types in the brain to make new oligodendrocytes, which are the only brain cells that produce myelin. It also lessens neuroinflammation common in MS.

Both of these events are necessary for the enhancement of remyelination by fractalkine, which Voronova said is predicted to halt the disease progression, and maybe even reverse some of the neurological symptoms that are associated with MS.

Voronova described the existing progenitor cells as lazy. They should know how to regenerate oligodendrocytes for remyelination, but are inefficient especially in MS patients.

Myelin deficiencies are detected in a variety of neurological disorders, such as Huntingtons, Parkinsons, and Alzheimers disease. Myelin deficiencies can also be found in neurodevelopmental disorders, including autism, schizophrenia, epilepsy, and traumatic brain injuries.

What we are also excited about is whether we can test the ability of fractalkine to promote brain regeneration in mouse models of other neurological disorders. Maybe this could be translated to a variety of different conditions, and not just something specific for MS, Voronova said.

Voronova and her research team are searching for ways to deliver fractalkine to the brain, such as a nasal spray.

Fractalkine is the molecule of interest in her recent study. But, Voronovas research program aims to discover new molecules that can trigger progenitor cells to cause brain regeneration.

Stem cells are set aside during embryonic brain development. But, they do not have a fixed function and are otherwise dormant throughout adulthood. The question of whether it is possible to resurrect embryonic cues in adult stem cells for use in neural regeneration drives Voronovas research.

This was actually a serendipitous discovery I started my journey in science by asking how do stem cells behave during brain development?

Voronova wanted to understand how neural stem cells communicate with neurons in close proximity within the developing brain.

I discovered that these neurons were secreting so many different molecules including fractalkine that then instructed the neural stem cells to make oligodendrocytes in the developing brain, she said.

Now my research program is built on translating this developmental discovery to engage the adult neural stem cells for brain regeneration.

The process of reactivating these embryonic cues remains unknown, but Voronova is making progress with her research.

I think it was 30 years ago it was realized that we have adult neural stem cells. We didnt know what they were doing there. And now, I think we definitely understand their promise. But, we dont necessarily understand how to harness the promise, Voronova said.

Its learning the signalling molecules and signalling pathways that were once important in the embryonic [stages] of brain development and then seeing whether I can reactivate those same signalling pathways in the adult brain, as well.

Every year,The Gatewaypublishes hundreds of articles like the one you just read that are free for everyone to access. ButThe Gatewayneeds your support to continue publishing its award-winning journalism. Please consider donating today, even a small amount can help the University of Albertas only newspaper continue serving the campus community. Thank you.

Continue reading here:
Brain molecule could reverse damage in multiple sclerosis, U of A ... - The Gateway Online